SynthesisThe Lancet. Oncology2023

Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.

Claire L Vale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.